Close Menu

Adaptive Biotechnologies

Of the 31 companies in the index, 11 firms saw their stock prices increase, while 20 saw their share prices decline.

The test leverages immune repertoire sequencing technology to identify individuals who have had a recent or prior SARS-CoV-2 infection.

Adaptive Cofounder and Chief Scientific Officer Harlan Robins compared the launch of the test to the unveiling of the Tesla Roadster electric sports car.

The immune cell sequencing company beat Wall Street estimates on the top line, but missed on the bottom line for both Q4 and full-year 2020.

The expanded partnership includes a commercial agreement for the ClonoSeq and ImmunoSeq assays, as well as a lab service agreement for the T-Detect COVID test.

Of the 32 companies in the index, 27 firms saw their stock prices increase, while 5 saw their share prices decline.

Among firms presenting on the first day, Roche provided insights into its COVID-19 testing business, and Guardant said it plans to launch a comprehensive tissue sequencing assay. 

Adaptive is rebranding its immunoSeq Dx assay as T-Detect and plans to submit for an EUA for a COVID-19 T-Cell response test by the end of the year.

In a non-exclusive deal, GlaxoSmithKline will use Adaptive Biotechnology's NGS-based ClonoSeq test to assess MRD across its hematology portfolio.

Development revenues for the Seattle-based firm ticked up 5 percent to $15.0 million in Q3, partially offset by a 3 percent dip in sequencing revenues.

Pages